Kalmeda from mynoise GmbH is the first approved app for behavioural tinnitus therapy.
With
M-Sense is an established headache and migraine app, which provides patients with a chronic pain diary with analysis tools and preventive recommendations.
Rehappy is a tool developed for the aftercare of stroke patients.
somnio is the DiGA which can be used for non-organically triggered sleep disorders and helps to optimise sleep rhythms and obstacles.
The movement therapy app
Vivira from Vivira Health Lab treats back, knee and hip pain caused, for example, by arthrosis, but also non-specific pain around the spine, hips, knees and back.
The application
中国疫苗加大出口力度 专家称助人亦为己 | 德国之声 来自德国 介绍德国 | DW dw.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dw.com Daily Mail and Mail on Sunday newspapers.
08:49 AM
Digital healthcare regulators, experts and developers discussed the Digital Health Applications (DiGA) process, and yesterday’s (24 Feb) Evidence Con session was designed to help innovators find out more about the new evidence requirements for the assessment of digital products in Germany.
The Federal Institute for Drugs and Medical Devices (BfArM) is responsible for the DiGA Fast-Track, which is now up and running. Eleven medical apps to help treat a range of conditions, such as tinnitus and insomnia, have already been listed - with an additional 55 in the certfication process.
WHY IT MATTERS
The DiGA Fast-Track was created by the 2019 Digital Healthcare Act and legislative changes mean that apps can now be prescribed by doctors and costs will be reimbursed through German health insurance. However, there are legal and regulatory hurdles to overcome before the apps can be listed and Data Protection Standards within German healthcare are strict.
Dubai: A series of virtual forums was launched by Dubai Health Authority (DHA) this week, in line with the UAE’s Innovation Month (UAE Innovates 2021).
Awadh Al Ketbi, the DHA Director-General, emphasised on the importance of fostering and promoting a culture of innovation, particularly in the health sector. He added: “Leveraging focus on research, new technologies, innovation and data analytics has a huge potential to advance health care to benefit both health-care providers and patients.”
He noted the DHA will continue to focus on health-care innovation to further advance the health sector and provide patient-centred care. Senior DHA officials, including Dr Alawi Alsheikh Ali, Deputy Director-General, and Dr Mohammed Al Redha, Director of Project Management Office, Informatics and Smart Health, attended the virtual forum.
HeraMED (ASX:HMD) will have its pregnancy monitoring solutions, HeraBEAT and HeraCARE, tested in a pilot study at Israel’s largest hospital, Sheba Medical Centre.